References

oncotomsk

Сибирский онкологический журнал

Siberian journal of oncology

1814-48612312-3168

Tomsk National Research Medical Сепtеr of the Russian Academy of Sciences

10.21294/1814-4861-2020-19-4-112-122

oncotomsk-1537

Research Article

ОБЗОРЫ

REVIEWS

МЕТОДЫ РАННЕЙ ДИАГНОСТИКИ РАКА ЛЕГКОГО (ОБЗОР ЛИТЕРАТУРЫ)

METHODS FOR EARLY DETECTION OF LUNG CANCER (REVIEW)

https://orcid.org/0000-0003-4980-8986

Родионов

Е. О.

Rodionov

E. O.

Родионов Евгений Олегович, кандидат медицинских наук, старший научный сотрудник торакального отделения; ассистент кафедры онкологии SPIN-код: 7650-2129. AuthorID (РИНЦ): 805452. Researcher ID (WOS): B-7280-2017. Author ID (Scopus): 57189622130.

634009, г. Томск, пер. Кооперативный, 5;634050, г. Томск, Московский тракт, 2

Evgenii O. Rodionov, MD, PhD, Senior Researcher, Thoracic Department; Assistant of the Department of Oncology Researcher ID (WOS): B-7280-2017. Author ID (Scopus): 57189622130.

5, Kooperativny Street, 634050-Tomsk;2, Moskovsky Trakt, 634050-Tomsk

rodionov_eo@oncology.tomsk.ru

https://orcid.org/0000-0002-0884-1838

Тузиков

С. А.

Tuzikov

S. A.

Тузиков Сергей Александрович, доктор медицинских наук, профессор, заведующий торакальным отделением; профессор кафедры онкологии SPIN-код: 5662-6431. AuthorID (РИНЦ): 455003. Researcher ID (WOS): D-1176-2012. Author ID (Scopus): 6507842873.

634009, г. Томск, пер. Кооперативный, 5;634050, г. Томск, Московский тракт, 2

Sergey A. Tuzikov, MD, DSc, Professor, Head of Thoracic Department; Professor of the Department of Oncology Researcher ID (WOS): D-1176-2012. Author ID (Scopus): 6507842873.

5, Kooperativny Street, 634050-Tomsk;2, Moskovsky Trakt, 634050-Tomsk

https://orcid.org/0000-0002-5365-9840

Миллер

С. В.

Miller

S. V.

Миллер Сергей Викторович, доктор медицинских наук, ведущий научный сотрудник торакального отделенияSPIN-код: 6510-9849. AuthorID (РИНЦ): 558789. Researcher ID (WOS): C-8970-2012. Author ID (Scopus): 56525429400.

634009, г. Томск, пер. Кооперативный, 5.

Sergey V. Miller, MD, DSc, Leading Researcher, Thoracic Department Researcher ID (WOS): C-8970-2012. Author ID (Scopus): 56525429400.

5, Kooperativny Street, 634050-Tomsk

https://orcid.org/0000-0003-3089-5047

Кульбакин

Д. Е.

Kulbakin

D. E.

Кульбакин Денис Евгеньевич, кандидат медицинских наук, старший научный сотрудник отделения опухолей головы и шеи SPIN-код: 3898-9456. AuthorID (РИНЦ): 557916. Researcher ID (WOS): D-1151-2012. Author ID (Scopus): 55534205500.

634009, г. Томск, пер. Кооперативный, 5.

Denis E. Kulbakin, MD, PhD, Senior Researcher, Department of Head and Neck Tumors Researcher ID (WOS): D-1151-2012. Author ID (Scopus): 55534205500.

5, Kooperativny Street, 634050-Tomsk

https://orcid.org/0000-0001-8753-7916

Чернов

В. И.

Chernov

V. I.

Чернов Владимир Иванович, доктор медицинских наук, профессор, руководитель отделения радионуклидной диагностики,заместитель директора по научной и инновационной работе; ведущий научный сотрудникSPIN-код: 6301-3612. AuthorID (РИНЦ): 108949. Researcher ID (WOS): B-6789-2016. Author ID (Scopus): 7201429550

634009, г. Томск, пер. Кооперативный, 5;634050, г. Томск, пр. Ленина, 30

Vladimir I. Chernov, MD, Professor, Head of the Department of Nuclear Medicine; Leading Researcher Researcher ID (WOS): B-6789-2016. Author ID (Scopus): 7201429550.

5, Kooperativny Street, 634050-Tomsk; 30, Lenin Ave, 634050-Tomsk

Научно-исследовательский институт онкологии, Томский национальный исследовательский медицинский центр Российской академии наук; ФГБОУ ВО «Сибирский государственный медицинский университет» Минздрава России,РоссияCancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences; Siberian State Medical UniversityRussian Federation

Научно-исследовательский институт онкологии, Томский национальный исследовательский медицинский центр Российской академии наукРоссияCancer Research Institute, Tomsk National Research Medical Center, Russian Academy of SciencesRussian Federation

Научно-исследовательский институт онкологии, Томский национальный исследовательский медицинский центр Российской академии наук; Национальный исследовательский Томский политехнический университетРоссияCancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences; National Research Tomsk Polytechnic UniversityRussian Federation

2020

01092020

194112122

2020

Родионов Е.О., Тузиков С.А., Миллер С.В., Кульбакин Д.Е., Чернов В.И.

Rodionov E.O., Tuzikov S.A., Miller S.V., Kulbakin D.E., Chernov V.I.

Данная работа распространяется под лицензией Creative Commons Attribution 4.0.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://www.siboncoj.ru/jour/article/view/1537

Objective: to generalize the world experience of lung cancer screening using modern diagnostic methods. Material and Methods. Literature search was performed in Medline, Cochrane Library, Elibrary, PubMed systems, including publications describing the current capabilities of laboratory, instrumental and molecular genetic methods for early diagnosis of lung cancer, 58 of which were used to write this review. Results. The review highlighted the results of international randomized trials of lung cancer screening using sputum Cytology and low-dose computed tomography. Special attention was paid to the description of modern molecular and genetic biomarkers of lung cancer, such as epigenetic markers, microRNAs, the use of proteomics technology, metabolomics, microbiome research, and biomarkers from liquid biopsy. The analysis of the world literature confirming the prospects of methods of non-invasive diagnostics of tumor processes based on the analysis of exhaled air was carried out. Conclusion. The use of modern screening methods will significantly improve the effectiveness of early diagnosis and, as a result, cancer treatment. Starting treatment at an early stage can significantly increase the patient’s chances of recovery and faster social and labor adaptation. As a non – invasive method of cancer diagnosis, an electronic nose can act as a set of gas sensors and a certain method of information processing. An electronic nose based on relatively cheap gas sensors has comparable accuracy, ease of data collection, mobility, and other advantages compared to the above mentioned devices.

рак легкогоскринингнизкодозная компьютерная томографиялетучие органические соединенияанализ выдыхаемого воздухаэлектронный нос

lung cancerscreeninglow-dose computed tomographyvolatile organic compoundsexhaled air analysiselectronic nose

Работа выполнена при финансовой поддержке Минобрнауки России, номер гранта в форме субсидии: 05.604.21.0221, уникальный идентификатор проекта – RFMEFI60419X0221

References1

Globocan 2018 [Internet]. Lyon, France: International Agency for Research on Cancer. Internet: http://globocan.iarc.fr (cited 13.03.2020).

Allemani C., Matsuda T., Di Carlo V., Harewood R., Matz M., Nikšić M., Bonaventure A., Valkov M., Johnson C.J., Estève J., Ogunbiyi O.J., Azevedo E., Silva G., Chen W.Q., Eser S., Engholm G., Stiller C.A., Monnereau A., Woods R.R., Visser O., Lim G.H., Aitken J., Weir H.K., Coleman M.P.; CONCORD Working Group. Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 populationbased registries in 71 countries. Lancet. 2018; 391(10125): 1023–75. doi: 10.1016/S0140-6736(17)33326-3.

Gervas P., Ivanova A., Vasiliev N., Ananina O., Cheremisina O., Popova N., Goldberg V., Choynzonov E., Cherdyntseva N., Zharkova O., Rogovieva O., Verzhbitskaya N., Didichuk I., Cherdyntsev E. Frequency of EGFR mutations in non-small cell lung cancer patients: screening data from West Siberia. Asian Pac J Cancer Prev. 2015; 16(2): 689–692. doi: 10.7314/APJCP.2015.16.2.689

Юмов Е.Л., Миллер С.В., Литвяков Н.В., Полищук Т.В., Тузиков С.А., Черемисина О.В., Гольдберг В.Е., Родионов Е.О. Химиотерапия в комбинированном лечении местнораспространенного немелкоклеточного рака легкого. Сибирский онкологический журнал. 2014; 2: 9–13.

Yumov Е.L., Miller S.V., Litvyakov N.V., Polischuk Т.V., Tuzikov S.A., Cheremisina О.V., Goldberg V.Е., Rodionov Е.О. Chemotherapy in combined modality treatment for locally advamced non-small cell lung cancer. Siberian Journal of Oncology. 2014; 2: 9–13. (in Russian).

Doria-Rose V.P., Marcus P.M., Szabo E., Tockman M.S., Melamed M.R., Prorok P.C. Randomized controlled trials of the efﬁcacy of lung cancer screening by sputum cytology revisited: a combined mortality analysis from the Johns Hopkins Lung Project and the Memorial Sloan-Kettering Lung Study. Cancer. 2009; 115(21): 5007–5017. doi: 10.1002/cncr.24545.

Fontana R.S., Sanderson D.R., Woolner L.B., Taylor W.F., Miller W.E., Muhm J.R. Lung cancer screening: the Mayo program. J Occup Med. 1986; 28(8): 746–750.

Melamed M.R., Flehinger B.J., Zaman M.B., Heelan R.T., Perchick W.A., Martini N. Screening for early lung cancer. Results of the Memorial SloanKettering study in New York. Chest. 1984; 86: 44–53.

Oken M.M., Marcus P.M., Hu P., Beck T.M., Hocking W., Kvale P.A., Cordes J., Riley T.L., Winslow S.D., Peace S., Levin D.L., Prorok P.C., Gohagan J.K. Baseline chest radiograph for lung cancer detection in the randomized Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. J Natl Cancer. Inst. 2005; 97(24): 1832–1839. doi: 10.1093/jnci/dji430.

Gouvinhas C., De Mello R.A., Oliveira D. Lung cancer: a brief review of epidemiology and screening. Future Oncol. 2018 Mar; 14(6): 567–575. doi: 10.2217/fon-2017-0486

National Lung Screening Trial Research Team, Aberle D.R., Adams A.M., Berg C.D., B.lack W.C., Clapp J.D., Fagerstrom R.M., Gareen I.F., Gatsonis C., Marcus P.M., Sicks J.D. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011 Aug 4; 365(5): 395–409. doi: 10.1056/NEJMoa1102873.

De Koning H., Van Der Aalst C., Ten Haaf K., Oudkerk M. PL02.05 Effects of volume ct lung cancer screening: mortality results of the nelson randomised-controlled population based trial. J Thorac Oncol. 2018; 13(10): S185.

Manser R., Lethaby A., Irving L.B., Stone C., Byrnes G., Abramson M.J., Campbell D. Screening for lung cancer. Cochrane Database Syst Rev. 2013 Jun 21; 2013(6): CD001991. doi: 10.1002/14651858.CD001991.pub3.

Black W.C., Gareen I.F., Soneji S.S., Sicks J.D., Keeler E.B., Aberle D.R., Naeim A., Church T.R., Silvestri G.A., Gorelick J., Gatsonis C.; National Lung Screening Trial Research Team. Cost-effectiveness of CT screening in the National Lung Screening Trial. N Engl J Med. 2014 Nov 6; 371(19): 1793–802. doi: 10.1056/NEJMoa1312547.

International Early Lung Cancer Action Program Investigators, Henschke C.I., Yankelevitz D.F., Libby D.M., Pasmantier M.W., Smith J.P., Miettinen O.S. Survival of patients with stage I lung cancer detected on CT screening. N Engl J Med. 2006 Oct 26; 355(17): 1763–71. doi: 10.1056/NEJMoa060476.

Brenner D.J. Radiation risks potentially associated with low-dose CT screening of adult smokers for lung cancer. Radiology. 2004 May; 231(2): 440–5. doi: 10.1148/radiol.2312030880.

Wang Memoli J.S., Nietert P.J., Silvestri G.A. Meta-analysis of guided bronchoscopy for the evaluation of the pulmonary nodule. Chest. 2012 Aug; 142(2): 385–393. doi: 10.1378/chest.11-1764.

Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther. 2001 Mar; 69(3): 89–95. doi: 10.1067/mcp.2001.113989.

Calabrese F., Lunardi F., Pezzuto F., Fortarezza F., Vuljan S.E., Marquette C., Hofman P. Are There New Biomarkers in Tissue and Liquid Biopsies for the Early Detection of Non-Small Cell Lung Cancer? J Clin Med. 2019 Mar 26; 8(3): 414. doi: 10.3390/jcm8030414.

Huang T., Li J., Zhang C., Hong Q., Jiang D., Ye M., Duan S. Distinguishing Lung Adenocarcinoma from Lung Squamous Cell Carcinoma by Two Hypomethylated and Three Hypermethylated Genes: A Meta-Analysis. PLoS One. 2016 Feb 10; 11(2): e0149088. doi: 10.1371/journal.pone.0149088.

Liu F., Zhang H., Lu S., Wu Z., Zhou L., Cheng Z., Bai Y., Zhao J., Zhang Q., Mao H. Quantitative assessment of gene promoter methylation in non-small cell lung cancer using methylation-sensitive high-resolution melting. Oncol Lett. 2018 May; 15(5): 7639–7648. doi: 10.3892/ol.2018.8321.

Ilse P., Biesterfeld S., Pomjanski N., Wrobel C., Schramm M. Analysis of SHOX2 methylation as an aid to cytology in lung cancer diagnosis. Cancer Genomics Proteomics. 2014 Sep-Oct; 11(5): 251–8.

Inamura K., Ishikawa Y. MicroRNA In Lung Cancer: Novel Biomarkers and Potential Tools for Treatment. J Clin Med. 2016; 5(3): 36. doi: 10.3390/jcm5030036.

Lu A., Zhang L. Tumor-Dependent and -Independent Serum/Plasma Biomarkers for Early Diagnosis of Lung Cancer. Transl Med. 2016; 6(1): 160. doi: 10.4172/2161-1025.1000160

Kim J.O., Gazala S., Razzak R., Guo L., Ghosh S., Roa W.H., Bédard E.L. Non-small cell lung cancer detection using microRNA expression profiling of bronchoalveolar lavage fluid and sputum. Anticancer Res. 2015 Apr; 35(4): 1873–80.

Bagheri A., Khorshid H.R.K., Tavallaie M., Mowla S.J., Sherafatian M., Rashidi M., Zargari M., Boroujeni M.E., Hosseini S.M. A panel of noncoding RNAs in non-small-cell lung cancer. J Cell Biochem. 2018 Nov 28. doi: 10.1002/jcb.28111.

Codreanu S.G., Hoeksema M.D., Slebos R.J.C., Zimmerman L.J., Rahman S.M.J., Li M., Chen S.C., Chen H., Eisenberg R., Liebler D.C., Massion P.P. Identification of Proteomic Features To Distinguish Benign Pulmonary Nodules from Lung Adenocarcinoma. J Proteome Res. 2017 Sep 1; 16(9): 3266–3276. doi: 10.1021/acs.jproteome.7b00245.

Nan Y., Du J., Ma L., Jiang H., Jin F., Yang S. Early Candidate Biomarkers of Non-Small Cell Lung Cancer Are Screened and Identified in Premalignant Lung Lesions. Technol Cancer Res Treat. 2017 Feb; 16(1): 66–74. doi: 10.1177/1533034615627391.

Li T., He J., Mao X., Bi Y., Luo Z., Guo C., Tang F., Xu X., Wang X., Wang M., Chen J., Abliz Z. In situ biomarker discovery and label-free molecular histopathological diagnosis of lung cancer by ambient mass spectrometry imaging. Sci Rep. 2015 Sep 25; 5: 14089. doi: 10.1038/srep14089.

Moreno P., Jiménez-Jiménez C., Garrido-Rodríguez M., Calderón-Santiago M., Molina S., Lara-Chica M., Priego-Capote F., Salvatierra Á., Muñoz E., Calzado M.A. Metabolomic profiling of human lung tumor tissues nucleotide metabolism as a candidate for therapeutic interventions and biomarkers. Mol Oncol. 2018 Oct; 12(10): 1778–1796. doi: 10.1002/1878-0261.12369.

Yu G., Gail M.H., Consonni D., Carugno M., Humphrys M., Pesatori A.C., Caporaso N.E., Goedert J.J., Ravel J., Landi M.T. Characterizing human lung tissue microbiota and its relationship to epidemiological and clinical features. Genome Biol. 2016 Jul 28; 17(1): 163. doi: 10.1186/s13059-016-1021-1.

Cameron S.J.S., Lewis K.E., Huws S.A., Hegarty M.J., Lewis P.D., Pachebat J.A., Mur L.A.J. A pilot study using metagenomic sequencing of the sputum microbiome suggests potential bacterial biomarkers for lung cancer. PLoS One. 2017 May 25; 12(5): e0177062. doi: 10.1371/journal.pone.0177062.

Hofman V., Ilie M.I., Long E., Selva E., Bonnetaud C., Molina T., Vénissac N., Mouroux J., Vielh P., Hofman P. Detection of circulating tumor cells as a prognostic factor in patients undergoing radical surgery for nonsmall-cell lung carcinoma: comparison of the efficacy of the CellSearch Assay™ and the isolation by size of epithelial tumor cell method. Int J Cancer. 2011 Oct 1; 129(7): 1651–60. doi: 10.1002/ijc.25819.

Xue Y., Cong W., Xie S., Shu J., Feng G., Gao H. Folate-receptorpositive circulating tumor cells as an efficacious biomarker for the diagnosis of small pulmonary nodules. J Cancer Res Ther. 2018; 14(7): 1620–1626. doi: 10.4103/jcrt.JCRT_905_17.

Ilie M., Hofman V., Long-Mira E., Selva E., Vignaud J.M., Padovani B., Mouroux J., Marquette C.H., Hofman P. «Sentinel» circulating tumor cells allow early diagnosis of lung cancer in patients with chronic obstructive pulmonary disease. PLoS One. 2014 Oct 31; 9(10): e111597. doi: 10.1371/journal.pone.0111597.

Shen J., Liu Z., Todd N.W., Zhang H., Liao J., Yu L., Guarnera M.A., Li R., Cai L., Zhan M., Jiang F. Diagnosis of lung cancer in individuals with solitary pulmonary nodules by plasma microRNA biomarkers. BMC Cancer. 2011 Aug 24; 11: 374. doi: 10.1186/1471-2407-11-374.

Yu H., Guan Z., Cuk K., Brenner H., Zhang Y. Circulating microRNA biomarkers for lung cancer detection in Western populations. Cancer Med. 2018 Oct; 7(10): 4849–4862. doi: 10.1002/cam4.1782.

Jin X., Chen Y., Chen H., Fei S., Chen D., Cai X., Liu L., Lin B., Su H., Zhao L., Su M., Pan H., Shen L., Xie D., Xie C. Evaluation of Tumor-Derived Exosomal miRNA as Potential Diagnostic Biomarkers for Early-Stage Non-Small Cell Lung Cancer Using Next-Generation Sequencing. Clin Cancer Res. 2017 Sep 1; 23(17): 5311–5319. doi: 10.1158/1078-0432.CCR-17-0577.

Hulbert A., Jusue-Torres I., Stark A., Chen C., Rodgers K., Lee B., Griffin C., Yang A., Huang P., Wrangle J., Belinsky S.A., Wang T.H., Yang S.C., Baylin S.B., Brock M.V., Herman J.G. Early Detection of Lung Cancer Using DNA Promoter Hypermethylation in Plasma and Sputum. Clin Cancer Res. 2017 Apr 15; 23(8): 1998–2005. doi: 10.1158/1078-0432.CCR-16-1371.

Vykoukal J., Sun N., Aguilar-Bonavides C., Katayama H., Tanaka I., Fahrmann J.F., Capello M., Fujimoto J., Aguilar M., Wistuba I.I., Taguchi A., Ostrin E.J., Hanash S.M. Plasma-derived extracellular vesicle proteins as a source of biomarkers for lung adenocarcinoma. Oncotarget. 2017 Sep 8; 8(56): 95466–95480. doi: 10.18632/oncotarget.20748.

Jia Z., Patra A., Kutty V.K., Venkatesan T. Critical Review of Volatile Organic Compound Analysis in Breath and In Vitro Cell Culture for Detection of Lung Cancer. Metabolites. 2019 Mar 18; 9(3): 52. doi: 10.3390/metabo9030052.

Gordon S.M., Szidon J.P., Krotoszynski B.K., Gibbons R.D., O'Neill H.J. Volatile organic compounds in exhaled air from patients with lung cancer. Clin Chem. 1985 Aug; 31(8): 1278–82.

Feinberg T., Alkoby-Meshulam L., Herbig J., Cancilla J.C., Torrecilla J.S., Gai Mor N., Bar J., Ilouze M., Haick H., Peled N. Cancerous glucose metabolism in lung cancer-evidence from exhaled breath analysis. J Breath Res. 2016 Jun 7; 10(2): 026012. doi: 10.1088/1752-7155/10/2/026012.

Handa H., Usuba A., Maddula S., Baumbach J.I., Mineshita M., Miyazawa T. Exhaled breath analysis for lung cancer detection using ion mobility spectrometry. PLoS One. 2014 Dec 9; 9(12): e114555. doi: 10.1371/journal.pone.0114555.

Phillips M., Cataneo R.N., Cummin A.R., Gagliardi A.J., Gleeson K., Greenberg J., Maxfield R.A., Rom W.N. Detection of lung cancer with volatile markers in the breath. Chest. 2003; 123(6): 2115–23. doi: 10.1378/chest.123.6.2115.

Wang C., Dong R., Wang X., Lian A., Chi C., Ke C., Guo L., Liu S., Zhao W., Xu G., Li E. Exhaled volatile organic compounds as lung cancer biomarkers during one-lung ventilation. Sci Rep. 2014 Dec 8; 4: 7312. doi: 10.1038/srep07312.

Peralbo-Molina A., Calderón-Santiago M., Priego-Capote F., Jurado-Gámez B., Luque de Castro M.D. Identification of metabolomics panels for potential lung cancer screening by analysis of exhaled breath condensate. J Breath Res. 2016 Mar 23; 10(2): 026002. doi: 10.1088/1752-7155/10/2/026002.

Hakim M., Broza Y.Y., Barash O., Peled N., Phillips M., Amann A., Haick H. Volatile organic compounds of lung cancer and possible biochemical pathways. Chem Rev. 2012 Nov 14; 112(11): 5949–66. doi: 10.1021/cr300174a.

de Lacy Costello B., Amann A., Al-Kateb H., Flynn C., Filipiak W., Khalid T., Osborne D., Ratcliffe N.M. A review of the volatiles from the healthy human body. J Breath Res. 2014 Mar; 8(1): 014001. doi: 10.1088/1752-7155/8/1/014001.

Ajibola O.A., Smith D., Spaněl P., Ferns G.A. Effects of dietary nutrients on volatile breath metabolites. J Nutr Sci. 2013 Oct 31; 2: e34. doi: 10.1017/jns.2013.26.

Trefz P., Kamysek S., Fuchs P., Sukul P., Schubert J.K., Miekisch W. Drug detection in breath: non-invasive assessment of illicit or pharmaceutical drugs. J Breath Res. 2017 Mar 20; 11(2): 024001. doi: 10.1088/1752-7163/aa61bf.

Schulz S., Dickschat J.S. Bacterial volatiles: the smell of small organisms. Nat Prod Rep. 2007 Aug; 24(4): 814–42. doi: 10.1039/b507392h.

Beauchamp J. Inhaled today, not gone tomorrow: pharmacokinetics and environmental exposure of volatiles in exhaled breath. J Breath Res. 2011; 5(3): 037103. doi: 10.1088/1752-7155/5/3/037103.

Haick H., Broza Y.Y., Mochalski P., Ruzsanyi V., Amann A. Assessment, origin, and implementation of breath volatile cancer markers. Chem Soc Rev. 2014 Mar 7; 43(5): 1423–49. doi: 10.1039/c3cs60329f.

Buist H.E., Wit-Bos L.D., Bouwman T., Vaes W.H. Predicting blood: air partition coefficients using basic physicochemical properties. Regul Toxicol Pharmacol. 2012 Feb; 62(1): 23–8. doi: 10.1016/j.yrtph.2011.11.019.

Schubert J.K., Miekisch W., Birken T., Geiger K., Nöldge-Schomburg G.F. Impact of inspired substance concentrations on the results of breath analysis in mechanically ventilated patients. Biomarkers. 2005 Mar-Jun; 10(2–3): 138–52. doi: 10.1080/13547500500050259.

Spaněl P., Dryahina K., Smith D. A quantitative study of the influence of inhaled compounds on their concentrations in exhaled breath. J Breath Res. 2013 Mar; 7(1): 017106. doi: 10.1088/1752-7155/7/1/017106.

Doran S.L.F., Romano A., Hanna G.B. Optimisation of sampling parameters for standardised exhaled breath sampling. J Breath Res. 2017 Dec 6; 12(1): 016007. doi: 10.1088/1752-7163/aa8a46..

Poli D., Carbognani P., Corradi M., Goldoni M., Acampa O., Balbi B., Bianchi L., Rusca M., Mutti A. Exhaled volatile organic compounds in patients with non-small cell lung cancer: cross sectional and nested short-term follow-up study. Respir Res. 2005 Jul 14; 6(1): 71. doi: 10.1186/1465-9921-6-71.

Peng G., Hakim M., Broza Y.Y., Billan S., Abdah-Bortnyak R., Kuten A., Tisch U., Haick H. Detection of lung, breast, colorectal, and prostate cancers from exhaled breath using a single array of nanosensors. Br J Cancer. 2010 Aug 10; 103(4): 542–51. doi: 10.1038/sj.bjc.6605810.

Kischkel S., Miekisch W., Sawacki A., Straker E.M., Trefz P., Amann A., Schubert J.K. Breath biomarkers for lung cancer detection and assessment of smoking related effects--confounding variables, influence of normalization and statistical algorithms. Clin Chim Acta. 2010 Nov 11; 411(21–22): 1637–44. doi: 10.1016/j.cca.2010.06.005.

Birken T., Schubert J., Miekisch W., Nöldge-Schomburg G. A novel visually CO2 controlled alveolar breath sampling technique. Technol Health Care. 2006; 14(6): 499–506.

Bikov A., Paschalaki K., Logan-Sinclair R., Horváth I., Kharitonov S.A., Barnes P.J., Usmani O.S., Paredi P. Standardised exhaled breath collection for the measurement of exhaled volatile organic compounds by proton transfer reaction mass spectrometry. BMC Pulm Med. 2013 Jul 9; 13: 43. doi: 10.1186/1471-2466-13-43.

Boshier P.R., Priest O.H., Hanna G.B., Marczin N. Influence of respiratory variables on the on-line detection of exhaled trace gases by PTRMS. Thorax. 2011 Oct; 66(10): 919–20. doi: 10.1136/thx.2011.161208.

Lärstad M.A., Torén K., Bake B., Olin A.C. Determination of ethane, pentane and isoprene in exhaled air--effects of breath-holding, flow rate and purified air. Acta Physiol (Oxf). 2007; 189(1): 87–98. doi: 10.1111/j.1748-1716.2006.01624.x.

Herbig J., Titzmann T., Beauchamp J., Kohl I., Hansel A. Buffered end-tidal (BET) sampling-a novel method for real-time breath-gas analysis. J Breath Res. 2008 Sep; 2(3): 037008. doi: 10.1088/1752-7155/2/3/037008.

Sukul P., Schubert J.K., Kamysek S., Trefz P., Miekisch W. Applied upper-airway resistance instantly affects breath components: a unique insight into pulmonary medicine. J Breath Res. 2017 Nov 1; 11(4): 047108. doi: 10.1088/1752-7163/aa8d86.

Thekedar B., Oeh U., Szymczak W., Hoeschen C., Paretzke H.G. Influences of mixed expiratory sampling parameters on exhaled volatile organic compound concentrations. J Breath Res. 2011 Mar; 5(1): 016001. doi: 10.1088/1752-7155/5/1/016001.

Wang Y., Hu Y., Wang D., Yu K., Wang L., Zou Y., Zhao C., Zhang X., Wang P., Ying K. The analysis of volatile organic compounds biomarkers for lung cancer in exhaled breath, tissues and cell lines. Cancer Biomark. 2012; 11(4): 129–37. doi: 10.3233/CBM-2012-00270.

Jordan A., Hansel A., Lindinger W., Holzinger R. Acetonitrile and benzene in the breath of smokers and non-smokers investigated by proton transfer reaction mass spectrometry (PTR-MS). Int. J. Mass Spectrom. Ion Process. 1995; 148: 68–70. doi:10.1016/0168-1176(95)04236-E.

Euler D.E., Davé S.J., Guo H. Effect of cigarette smoking on pentane excretion in alveolar breath. Clin Chem. 1996 Feb; 42(2): 303–8.

Zou Y., Zhang X., Chen X., Hu Y., Ying K., Wang P. Optimization of volatile markers of lung cancer to exclude interferences of nonmalignant disease. Cancer Biomark. 2014; 14(5): 371–9. doi: 10.3233/CBM-140418.

Corradi M., Poli D., Banda I., Bonini S., Mozzoni P., Pinelli S., Alinovi R., Andreoli R., Ampollini L., Casalini A., Carbognani P., Goldoni M., Mutti A. Exhaled breath analysis in suspected cases of nonsmall-cell lung cancer: a cross-sectional study. J Breath Res. 2015 Jan 29; 9(2): 027101. doi: 10.1088/1752-7155/9/2/027101.

Horváth I., Barnes P.J., Loukides S., Sterk P.J., Högman M., Olin A.C., Amann A., Antus B., Baraldi E., Bikov A., Boots A.W., Bos L.D., Brinkman P., Bucca C., Carpagnano G.E., Corradi M., Cristescu S., de Jongste J.C., Dinh-Xuan A.T., Dompeling E., Fens N., Fowler S., Hohlfeld J.M., Holz O., Jöbsis Q., Van De Kant K., Knobel H.H., Kostikas K., Lehtimäki L., Lundberg J., Montuschi P., Van Muylem A., Pennazza G., Reinhold P., Ricciardolo F.L.M., Rosias P., Santonico M., van der Schee M.P., van Schooten F.J., Spanevello A., Tonia T., Vink T.J. A European Respiratory Society technical standard: exhaled biomarkers in lung disease. Eur Respir J. 2017 Apr 26; 49(4): 1600965. doi: 10.1183/13993003.00965-2016.

Li Z., Askim J.R., Suslick K.S. The Optoelectronic Nose: Colorimetric and Fluorometric Sensor Arrays. Chem Rev. 2019 Jan 9; 119(1): 231–292. doi: 10.1021/acs.chemrev.8b00226.

Behera B., Joshi R., Anil Vishnu G.K., Bhalerao S., Pandya H.J. Electronic nose: A non-invasive technology for breath analysis of diabetes and lung cancer patients. J Breath Res. 2019 Mar 6; 13(2): 024001. doi: 10.1088/1752-7163/aafc77.

The authors declare that there are no conflicts of interest present.